Vol. 5 No. 9 (2025)
Reimbursement Reviews

Pertuzumab

Published September 12, 2025

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses pertuzumab, 840 mg loading dose and 420 mg maintenance dose, IV infusion.
  • Indication under consideration for reimbursement: Pertuzumab in combination with trastuzumab and chemotherapy for early-stage HER2-positive breast cancer in the neoadjuvant setting.